ICU Medical Q2 revenue falls to $548.9 million; adjusted EBITDA guidance top end cut
ICU Medical reported second quarter 2025 revenue of $548.9 million, down from $596.5 million a year earlier, and GAAP net income of $35.3 million, or $1.43 per diluted share, which included a $41.8 million gain on sale of a business. The company also narrowed its 2025 adjusted EBITDA guidance to $380 million to $390 million from $380 million to $405 million, and adjusted diluted EPS guidance to $6.85 to $7.15 from $6.55 to $7.25, so shareholders face lower revenue and a lower top end for adjusted EBITDA guidance despite higher reported profit.
Key points
- Q2 2025 revenue was $548.9 million versus $596.5 million in Q2 2024; Vital Care revenue fell to $108.0 million from $171.0 million.
- GAAP net income was $35.3 million, or $1.43 per diluted share, versus a net loss of $21.4 million, or $0.88 per share, a year earlier.
- Adjusted diluted EPS was $2.10 versus $1.56; adjusted EBITDA was $100.3 million versus $91.3 million.
- Full-year 2025 adjusted EBITDA guidance high end lowered to $390 million from $405 million; the low end stayed at $380 million.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:01 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.